Difference between metoprolol succinate and tartrate
Pro Research Analysisby 
Searched over 200M research papers
Differences Between Metoprolol Succinate and Metoprolol Tartrate
Introduction to Metoprolol Forms
Metoprolol is a beta-blocker commonly prescribed for various cardiovascular conditions, including hypertension, heart failure, and angina. It is available in two primary salt forms: metoprolol succinate and metoprolol tartrate. While both forms are used to manage similar conditions, they differ in their pharmacokinetics, dosing schedules, and clinical effects.
Pharmacokinetics and Dosing Schedules
Metoprolol Succinate
Metoprolol succinate is formulated as a sustained-release tablet, allowing for once-daily dosing. This extended-release formulation provides a more consistent therapeutic effect over 24 hours, which can be beneficial for patient compliance and maintaining stable blood levels of the medication 147.
Metoprolol Tartrate
In contrast, metoprolol tartrate is an immediate-release formulation that typically requires twice-daily dosing. This can lead to fluctuations in drug levels throughout the day, which might affect the consistency of therapeutic effects 147.
Clinical Efficacy and Safety
Heart Failure and Hemodynamic Effects
Both metoprolol succinate and tartrate have been shown to produce similar hemodynamic and clinical benefits in patients with congestive heart failure. Studies indicate that both forms improve cardiac function, exercise capacity, and overall hemodynamics without significant differences in adverse effects . However, metoprolol succinate may offer advantages in terms of more rapid initiation and ease of dosing .
Acute Myocardial Infarction
In patients with acute myocardial infarction, both forms of metoprolol effectively reduce heart rates and improve clinical outcomes. However, there is no significant difference in the degree and trend of heart rate reduction between the two formulations over the first 72 hours of treatment .
Chronic Obstructive Pulmonary Disease (COPD) with Heart Failure
For patients with COPD complicating chronic heart failure, metoprolol succinate has been found to be more effective in improving cardiac function compared to metoprolol tartrate, although both forms have similar safety profiles .
Vasospastic Angina
In the treatment of vasospastic angina, metoprolol succinate has shown a significant advantage in reducing the incidence of clinically significant angina attacks compared to metoprolol tartrate. However, there are no significant differences in the rates of adverse cardiovascular events such as myocardial infarction or stroke between the two forms .
Structural and Stability Differences
Solid-State Behavior
The solid-state structures of metoprolol succinate and tartrate differ significantly. Metoprolol succinate exhibits a reversible anisotropic lattice expansion/contraction upon temperature changes and quickly recrystallizes to its original form after melting. In contrast, metoprolol tartrate expands/contracts isotropically and forms an amorphous solid upon cooling, which takes several days to revert to its crystalline form 25. These differences can influence the stability and shelf-life of the medications.
Conclusion
While metoprolol succinate and metoprolol tartrate are both effective beta-blockers for managing cardiovascular conditions, they differ in their pharmacokinetics, dosing schedules, and some clinical outcomes. Metoprolol succinate's sustained-release formulation offers the convenience of once-daily dosing and may provide more stable therapeutic effects, making it a preferable option for certain patient populations. However, both forms are generally comparable in terms of efficacy and safety for most cardiovascular indications.
Sources and full results
Most relevant research papers on this topic